Availability of Weight-Loss Treatment

Following recent national announcements about weight-loss treatments, patients are encouraged to refer to the latest Information for patients on weight-loss treatment for accurate details.

Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board is working closely with primary care providers to ensure that this new treatment is offered to eligible patients and prioritised for those with the greatest clinical need.

Tirzepatide (sometimes referred to by the brand name Mounjaro®) will soon become available for use in primary care settings.

To be eligible, patients must have a body mass index (BMI) over 40 and have been diagnosed with at least four of the following conditions:

• Type 2 diabetes
• Hypertension
• Cardiovascular disease
• Obstructive sleep apnoea
• Dyslipidaemia